Association of antieosinophil therapy with decreased body mass index in patients with severe asthma A preliminary retrospective analysis

• Type of Material: Article
• Authors: Merin Kuruvilla, Emory University; Meera Patrawala, Emory University; Joshua Levy, Emory University; Jennifer Shih, Emory University; Frances Lee, Emory University
• Language: English
• Date: 2019-06-01
• Publisher: Elsevier Science Inc.
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.anai.2019.03.031
• Title of Journal or Parent Work: Annals of Allergy, Asthma & Immunology
• Volume: 122
• Issue: 6
• Start Page: 649
• End Page: 650
• Grant/Funding Information: None.
• Keywords: Life Sciences & Biomedicine; Eosinophils; Allergy; Science & Technology; Immunology
• Research Categories: Health Sciences, Public Health; Health Sciences, Health Care Management; Health Sciences, Immunology

Abstract

The type 2 high endotype of asthma with adult onset is often characterized by severe, persistent, steroid-refractory eosinophilic inflammation. Interleukin 5 (IL-5) is a pivotal cytokine for eosinophil survival. The amelioration of eosinophilic inflammation through anti—IL-5 therapies (mepolizumab, reslizumab, and ben-ralizumab) reduces exacerbations and improves control is and well tolerated overall.